ArticleBioengineering & translational medicine2025
Enhanced Schwann cell differentiation of skin-derived neural crest-like stem cells through the synergistic action of SOX10 and immobilized NRG1 signaling.
Article in Bioengineering & translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Plasticity, injury-induced reprogramming, and translational applications of Schwann cells in neural regeneration.Frontiers in cellular neuroscience · 2026Review
- Enhanced Schwann cell differentiation of skin-derived neural crest-like stem cells through the synergistic action of SOX10 and immobilized NRG1 signaling.Bioengineering & translational medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Human skin-derived neural crest (NC)-like stem cells present a highly accessible, autologous source of multipotent cells, with the potential to differentiate into a variety of cell types, including Schwann cells (SCs). However, these cells quickly lose their stem-like characteristics in vitro and eventually limit their ability to form functional SCs. To overcome this, we investigated SOX10 upregulation, the key regulator of NC formation and multipotency, using both small chemical (Forskolin and RepSox) treatment and genetic modification. Remarkably, SOX10 upregulation highly increased SC gene expression instead of NC markers, though Forskolin-RepSox also triggered melanocytic and smooth muscle gene markers alongside reduced NC genes. In contrast, genetic SOX10 upregulation enhanced both SOX10 and NC gene expression without inducing alternative lineages. Continuous SOX10 expression was necessary for increased SC protein markers, and differentiating SOX10-overexpressing cells on immobilized NRG1 further enhanced SC markers and induced a distinct, elongated morphology typical for myelinating SCs. Therefore, this study introduces a rapid, efficient method to derive SC-like cells from the skin-derived NCs, highlighting their potential in regenerative medicine for cell therapy and disease modeling applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.